Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Genmab, de Deense parel
Volgen
slot koers DKK 355,-. Omzet (al weer) 1,2 miljoen stukjes. Dit gaat nog wel even door.
Genmab koersen (Deense beurs) zijn ook te volgen via yahoo.finance.yahoo.com/q?s=GEN.CO
Synopsis We initiate coverage on Danish biotech company Genmab with a BUY recommendation and a 12- month price target of DKK 425. With four products in Phase III, the company has by far the most promising pipeline in cancer in the European biotech sector. Major deals are to be expected in the coming period.
Hoogste koers vandaag 375 Dkr . Op naar de 425 Dkr. Jo.
Ja, ja, maar nu wel even consolideren. Die 375 was te hoog gegrepen. De range tot zoverre vandaag: 349.50 - 375.00 Last Trade: 350.00 Misschien dat we even iets terug moeten. Q: wanneer krijgen we dat TO bod voor 425 ?
Dat TO bod mag van mij nog voor het einde van dit jaar komen. Genmab moet inderdaad even terug. De omzetten blijven hoog, doch iets minder dan tijdens de stijging. Ik had er zelf ook al aan gedacht om tussentijds even uit te stappen, maar heb het niet gedaan. Genmab is zwanger van goed nieuws. Zo kunnen er ieder moment (nieuwe) partners worden bekend worden gemaakt voor de diverse medicijnen in ontwikkeling. Ook dan kunnen we, zonder TO, rap naar de DKK 400,- Let wel Genmab heeft niet direct partners nodig. Het bedrijf is een van de financieel gezondste biotechbedrijven wereldwijd. demo
Het bod zal beslist hoger moeten zijn dan 425 per aandeel! Dit zou een spotprijs zijn om het bedrijf over te nemen. De markt voor hun meest belovende geneesmiddel is groter dan de waarde van het hele bedrijf... you do the maths... ik verkoop niet, ook niet tussentijds ;-)
Genmab heeft grote deal gesloten met Glaxon Smith K. voor 2.1bln dollar !! | Print | Glaxo signs $2.1 bln deal for Genmab's lead drug LONDON, Dec 19 (Reuters) - GlaxoSmithKline Plc has bought global rights to Danish biotech company Genmab's most promising new drug, a treatment for leukemia, in a deal worth up to $2.1 billion, the two firms said on Tuesday. The deal covers HuMax-CD20, an experimental antibody medicine in late-stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma. It is also in Phase II trials for rheumatoid arthritis. ((Reporting by Ben Hirschler; email: ben.hirschler@reuters.com ; Reuters Messaging: ben.hirschler.reuters.com@reuters.net ; +44 20 7542 5082)) Keywords: GLAXO GENMAB/ Distributed by ©Reuters Limited. Click for Restrictions.
Dat is TOPnieuws. Anderzijds lijkt het erop, dat Genmab (nog) niet verkocht gaat worden. Op Yahoo zie ik ook: GSK paying DK 454,68 per share, a 33% premium to yesterday's closing price. Begrijp ik nog niet. Koers vrijwel onveranderd... Begrijp ik ook nog niet... ________________________________________________________________________ GLAXOSMITHKLINE AND GENMAB ENTER GLOBAL AGREEMENT FOR HUMAX-CD20 London, UK & Philadelphia, USA and Copenhagen, Denmark; December 19, 2006 - GlaxoSmithKline (GSK) and Genmab A/S (CSE:GEN) today announced a worldwide agreement to co-develop and commercialize HuMax-CD20™ (ofatumumab), a fully human monoclonal antibody in late stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma (NHL) and in Phase II for rheumatoid arthritis (RA). Under the terms of the agreement, Genmab will receive a license fee of DKK 582 million (approximately £ 52 million and approximately $102 million*), and GSK will invest DKK 2,033 million (approximately £ 183 million and approximately $357 million) to purchase, 4,471,202 ordinary shares of Genmab. The total potential value of this agreement, in the event of full commercial success, in cancer and various autoimmune and inflammatory diseases, could exceed DKK 12.0 billion (approximately £ 1.1 billion and approximately $2.1 billion), including the initial license fee and equity purchase, milestone payments, totaling DKK 9.0 billion (approximately £ 0.8 billion and approximately $ 1.6 billion) and expected development, commercial manufacturing and commercialization costs. In addition, Genmab will be entitled to receive tiered double digit royalties on global sales of HuMax-CD20. GSK will receive an exclusive worldwide license to HuMax-CD20 as well as any other antibodies with affinity for the CD20 antigen which Genmab may develop. GSK will also have an exclusive option to a CD20 UniBody™ to be developed in collaboration with Genmab. GSK and Genmab will co-develop HuMax-CD20. Genmab will be responsible for development costs until 2008, including costs of the two ongoing late stage oncology studies after which development costs will be shared equally between GSK and Genmab. GSK will be solely responsible for the manufacturing and commercialization of HuMax-CD20. Genmab will have an option to co-promote HuMax-CD20 in a targeted oncology setting in the US and in the Nordic region. Should this be undertaken, Genmab will also have the option co-promote Bexxar™ and Arranon™ in the US and Atriance™ in the relevant countries of the Nordic region.
Koers Genmab: 15 % Up... dat gaat leuk worden GEN.CO 410.50 +68.50
ja ik vind het ook wel raar dat de koers niet meer gestegen is... laten we nu maar hopen dat een conccurrent van glaxo een overnamebod doet, dan kunnen we kerst vieren!
Klopt denk wel ongeveer. Number of shares: 39,648,355 En GSK koopt: 4,471,202 aandelen voor DKK 2,033 million. Maw GSK koopt zo'n 15 % van totaal aantal aandelen, dus koers gaat dan niet gelijk naar de koers betaald door GSK. Dit lijkt me een goeie deal. De speculatie was DK 425 voor TO bod. Nu al @ 410, dat zal wel verder stijgen, vooral als duidelijk wordt dat deze drug op de markt komt. Kiter27 schreef:
ja ik vind het ook wel raar dat de koers niet meer gestegen is...
Reuters PB: Glaxo signs record $2.1 bln deal for Genmab drug Tuesday December 19, 4:31 am ET By Ben Hirschler, European Pharmaceuticals Correspondent LONDON (Reuters) - GlaxoSmithKline Plc (London:GSK.L - News) has bought global rights to Danish biotech company Genmab's (Copenhagen:GEN.CO - News) most promising new drug, a treatment for leukemia, in a record deal worth up to $2.1 billion, the two firms said on Tuesday. The agreement is the biggest ever clinched by a biotech company, eclipsing a $2-billion alliance between ImClone Systems Inc. (NASDAQ:IMCL - News) and Bristol-Myers Squibb Co. (NYSE:BMY - News) that was revised down in 2002 when ImClone's drug Erbitux hit snags. Genmab shares surged as much as 24 percent to a new all-time high of 424 Danish crowns in early trading, valuing the business -- which has yet to make a profit -- at close to $3 billion. The deal is the latest in a string of product acquisitions by large pharmaceutical firms eager to tap biotech know-how to boost their drug pipelines, and the price paid reflects the fierce competition for late-stage assets. It covers HuMax-CD20, an experimental human antibody in late-stage development for CD20 positive B-cell chronic lymphocytic leukemia and follicular non-Hodgkin's lymphoma. The drug, which is also in Phase II trials for rheumatoid arthritis, is similar to MabThera/Rituxan from Roche Holding AG (ROG.VX) and Genentech Inc. (NYSE:DNA - News). Genmab's chief executive said she was confident HuMax-CD20, which is expected to be filed for regulatory approval by 2008, could generate well over $2 billion in annual sales. "I think potential sales are higher than that and when you see the deal value, you can see that they (Glaxo) believe (that) also," Lisa Drakeman told Reuters in a telephone interview. Some analysts have penciled in potential sales of as much as $5 billion in cancer and arthritis, she noted. Jyske Bank analyst Frank Andersen, who forecasts peak sales of $2.8 billion, raised his rating on Genmab shares to "buy" from "accumulate" on the deal, saying that regulatory approval for HuMax-CD20 for its three uses would put a fair value of 470 crowns on the stock. The Danish group had been expected to strike a deal for the product by the middle of 2007. Under the agreement with Glaxo it will receive a license fee of 582 million Danish crowns ($102 million) and Glaxo will invest approximately $357 million to buy shares in Genmab. Genmab is also entitled to milestone payments of up to $1.6 billion, based on the drug's successful development and commercialization and will receive tiered double-digit percentage royalties on global sales of the medicine. GLAXO'S ANTIBODY DRIVE The deal is the second struck by Glaxo in the fast-growing antibody arena in less than two weeks, following its agreement to buy early-stage drug firm Domantis for 230 million pounds ($449 million) on December 8. Europe's biggest drugmaker has been under-represented in biological medicines, such as antibodies, in the past. In addition to winning rights to a promising new drug that could join its growing cancer portfolio in the near future, the tie-up with Genmab also increases Glaxo's presence in next-generation antibody technology, since it will have an exclusive option to CD20 UniBody. Unibody is a new antibody technology developed by Genmab offering a smaller format, which means it may work more effectively than existing monoclonal antibodies. This dovetails with Domantis's similar ultra-small antibody technology. Genmab is to maintain a key role in the future of HuMax-CD20 in an arrangement that underlines the strong negotiating hand of successful biotech companies. It will be responsible for development costs until 2008 and will have an option to co-promote HuMax-CD20 as a cancer treatment in the United States and the Nordic region. Genmab will also have an option to co-promote Glaxo's drugs Bexxar and Arranon in the United States and Atriance in Nordic countries.
jammer van de verwatering ;-( Ik had toch liever een overname gezien van bestaande aandelen.
Om 3:30pm de Conference Call via Genmab web-sitecis.premconf.com/sc/scw.dll/?sid=3559...
Hoe handel jij in het aandeel Genmab? Via Alex?
Via ABN Amro kun je handelen (tradebox of internet).www.volghetgeld.nl/artikel.php?artid=169
niet veel nieuws op de persconferentie. Het enige wat ik eruit onthoud is dat er nog deals zullen aankomen voor de andere produkten in de pijplijn
heb op 405 verkocht nog net iets te vroeg ( vorig jaar gekocht op 115)heb nu op 360 ingelegd
Leuk he zo'n heftig ritje. Het nieuws m.b.t. tot het aankondigen van een partner zat er al een tijdje aan te komen. Overname wordt hierdoor een stukje onwaarschijnlijker in mijn ogen. Wie wil er nu met een deal met de concurrentie worden geconfronteerd ?? Ben even uitgestapt, maar kom beslist terug. Hopenlijk p een iets lagere koers, na winstnemingen. Maar desnoods tegen een hogere koers. Het potentieel uit dit aandeel is nog lang niet op. prettige feestdagen en alvast een voorspoedig beleggingsjaar.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,59
+0,71%
EUR/USD
1,0771
0,00%
FTSE 100
8.433,76
+0,63%
Germany40^
18.773,50
+0,47%
Gold spot
2.360,72
0,00%
NY-Nasdaq Composite
16.340,87
-0,03%
Stijgers
Dalers